Brief: Lumos Pharma Reports Q1 Loss Per Share Of $0.14

Lumos Pharma

28/05/2020 21:07

May 28 (Reuters) - Lumos Pharma Inc  LUMO.O :
    * LUMOS PHARMA REPORTS FIRST QUARTER 2020 RESULTS AND
PROVIDES
UPDATE ON CLINICAL AND CORPORATE ACTIVITIES
    * LUMOS PHARMA- EXPECTS TO INITIATE ITS PHASE 2B LUM-201
TRIAL IN
PEDIATRIC GROWTH HORMONE DEFICIENCY (PGHD) PRIOR TO END OF 2020
    * LUMOS PHARMA INC - ADDITIONAL NON-DILUTIVE FUNDS EXPECTED
FROM
ANTICIPATED MONETIZATION OF PRIORITY REVIEW VOUCHER (PRV)
    * LUMOS PHARMA INC - CASH ON HAND EXPECTED TO FUND CURRENT
OPERATIONS THROUGH PHASE 2B TRIAL READ-OUT
    * LUMOS PHARMA INC - CONTINUES TO PRIORITIZE CLINICAL
DEVELOPMENT
OF LUM-201
    * LUMOS PHARMA INC - NOW EXPECTS TO INITIATE PHASE 2B
CLINICAL
TRIAL IN PGHD PRIOR TO END OF 2020
    * LUMOS PHARMA INC - QTRLY LOSS PER SHARE $0.14

Source text for Eikon:  ID:nGNX7vfzQ6 
Further company coverage:  LUMO.O 

 ((Reuters.Briefs@thomsonreuters.com;))